Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)

Annals of the Rheumatic Diseases

Volumn 75, Issue 11, 2016, Pages 1917-1923

  Kaneko, Yuko ^a   Atsumi, Tatsuya ^b   Tanaka, Yoshiya ^c   Inoo, Masayuki ^d   Kobayashi Haraoka, Hitomi ^e   Amano, Koichi ^f   Miyata, Masayuki ^g   Murakawa, Yohko ^h   Yasuoka, Hidekata ^a   Hirata, Shintaro ^c   Nagasawa, Hayato ^f   Tanaka, Eiichi ⁱ   Miyasaka, Nobuyuki ^j   Yamanaka, Hisashi ⁱ   Yamamoto, Kazuhiko ^k   Takeuchi, Tsutomu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d Utazu Clinic   (Japan)

^e NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

^g Fukushima Red Cross Hospital   (Japan)

^h SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

ⁱ TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^j TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Disease Activity; DMARDs (biologic); Rheumatoid Arthritis; Treatment

Indexed keywords

METHOTREXATE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; MONOCLONAL ANTIBODY;

ABNORMAL LABORATORY RESULT; ADD ON THERAPY; ADULT; ARTICLE; BACTERIAL PNEUMONIA; BENIGN TUMOR; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; INJURY; INTOXICATION; LIVER FUNCTION DISORDER; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEOPLASM; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SCORING SYSTEM; SKIN DISEASE; SOFT TISSUE DISEASE; THORAX DISEASE; TREATMENT RESPONSE; VAN DER HEIJDE MODIFIED TOTAL SHARP SCORING SYSTEM; ARTHRITIS, RHEUMATOID; BLOOD; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG SUBSTITUTION; MIDDLE AGED; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DISEASE PROGRESSION; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84956630876     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208426     Document Type: Article

References (21)

1. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
2. Smolen JS, Aletaha D, Bijlsma JW, et al., T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force Ann Rheum Dis 2010;69:631-7
3. Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med 2011;60:75-81
4. Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug? Autoimmun Rev 2014;13:1102-8
5. Klareskog L, van der Heijde D, de Jager JP, et al., TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81
6. Kameda H, Kanbe K, Sato E, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study J Rheumatol 2011;38:1585-92
7. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
8. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69:88-96
9. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-19
10. Burmester G, Rigby W, van Vollenhoven R, et al. Tocilizumab (TCZ) in combination and monotherapy versus methotrexate (MTX) in MTX-naïve patients (PTS) with early rheumatoid arthritis (RA): Clinical and radiographic outcomes from a randomized, placebo-controlled trial. Ann Rheum Dis 2013;72(Suppl 3):A63
11. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50
12. Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: The ACT-RAY study. Ann Rheum Dis 2014;73:803-9
13. Weinblatt ME, Kremer J, Cush J, et al. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: Twenty-four-week results of an open-label, clinical practice study. Arthritis Care Res (Hoboken) 2013;65:362-71
14. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-Analysis of six initial trials and five long-Term extensions. Mod Rheumatol 2010;20: 222-32
15. Maini RN, Taylor PC, Szechinski J, et al., CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29
16. Yamanaka H, Ishiguro N, Takeuchi T, et al. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-Treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial Rheumatology (Oxford) 2014;53:904-13
17. Bykerk VP, Ostör AJ, Alvaro-Gracia J, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: A large, open-label study close to clinical practice. Ann Rheum Dis 2012;71:1950-4
18. Kameda T, Dobashi H, Miyatake N, et al. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2014;66:1302-9
19. Tokuhira M, Watanabe R, Nemoto T, et al. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-Associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma 2012;53:616-23
20. Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 2013;91:20-8
21. Takahashi C, Kaneko Y, Okano H, et al. Methotrexate polyglutamates in erythrocytes correlates with clinical response in Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2014;73(Suppl 2):218-19